Coexistence of hepatoma with mantle cell lymphoma in a hepatitis B carrier

Lee, Mu-Hsien; Lin, Yu‐Ching; Cheng, Hao‐Tsai; Chuang, Wen-Yu; Huang, Hsien‐Cheng; Kao, Hsiao‐Wen

doi:10.3748/wjg.v21.i45.12981

Cited by 3 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The coexistence of lymphomas and HCC has been mostly reported in clinical patients infected with hepatitis virus [ 67 , 68 ], while cohort studies and case–control studies have consistently reported that the increased risks of both HCC and lymphoma are associated with infection of HCV or HBV [ 69 – 72 ]. A Danish HCV cohort (DANVIR) cohort study of liver cancer and non-Hodgkin lymphoma was performed in HCV-infected patients [ 73 ].…”

Section: Secondary Lymphomasmentioning

confidence: 99%

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases

Shi

Wang

et al. 2022

Cell Biosci

View full text Add to dashboard Cite

With inconsistent findings, evidence has been obtained in recent years that metabolic disorders are closely associated with the development of lymphomas. Studies and multiple analyses have been published also indicating that some solid tumor survivors develop a secondary lymphoma, whereas some lymphoma survivors subsequently develop a second malignant neoplasm (SMN), particularly solid tumors. An interaction between the multiple etiologic factors such as genetic factors and late effects of cancer therapy may play an important role contributing to the carcinogenesis in patients with metabolic diseases or with a primary cancer. In this review, we summarize the current knowledge of the multiple etiologic factors for lymphomagenesis, focusing on the SMN in lymphoma, secondary lymphomas in primary cancers, and the lymphomas associated to metabolic disorders/diseases, which have been received less attention previously. Further, we also review the data of coexistence of lymphomas and hepatocellular carcinoma (HCC) in patients with infection of hepatitis C virus and hepatitis B virus. Graphical Abstract

show abstract

Section: Secondary Lymphomasmentioning

confidence: 99%

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases

Shi

Wang

et al. 2022

Cell Biosci

View full text Add to dashboard Cite

show abstract

Concomitant hepatocellular carcinoma recurrence and mantle cell lymphoma

Xue

Wan

et al. 2024

Hepatobiliary & Pancreatic Diseases International

View full text Add to dashboard Cite

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma

Dong

Pan

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundAs an emerging therapy with a promising efficacy, immunotherapy has been widely used in the treatment of solid tumors and hematologic malignancies. This clinical study compares the efficacy of tislelizumab, a domestic immune checkpoint inhibitor (ICI), to that of sorafenib when used as a first-line therapeutic option in hepatocellular carcinoma (HCC), and the concurrence of HCC and non-Hodgkin’s lymphoma (NHL) is rare, especially in the treatment of ICIs.Case presentationA 61-year-old patient presenting with primary HCC and indolent B-cell lymphoma had a partial clinical response to tislelizumab for his primary HCC. Besides, we described a phenomenon of pseudo-progression and delayed diagnosis of his lymphoma during a long course of treatment.ConclusionTislelizumab, an immunotherapeutic option with a favorable efficacy and toxicity, can be used to manage double primary tumors. However, studies should aim to elucidate the probable mechanisms of this therapy. Pseudo-progression and separation remission make the treatment of double primary tumors even more challenging, which calls for additional caution in patients undergoing immunotherapy to avoid misdiagnosis and, therefore, begin early appropriate interventions.

show abstract

Coexistence of hepatoma with mantle cell lymphoma in a hepatitis B carrier

Cited by 3 publications

References 21 publications

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases

Second malignant neoplasms in lymphomas, secondary lymphomas and lymphomas in metabolic disorders/diseases

Concomitant hepatocellular carcinoma recurrence and mantle cell lymphoma

Case Report: Clinical Responses to Tislelizumab as a First-Line Therapy for Primary Hepatocellular Carcinoma With B-Cell Indolent Lymphoma

Contact Info

Product

Resources

About